Clinical Trials Directory

Trials / Unknown

UnknownNCT04582487

Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
32 (estimated)
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a biological study for R/R T-ALL/LBL or ETP-ALL patients. Bone marrow and/or peripheral blood samples will be subjected to genomic, DSRP profiling and phosphoproteomic screening to identify novel potential therapeutic approach and thus, eligibility for treatment based on molecular and DSRP data. As soon as genomic and DSRP profiling are made available, local Investigator can submit to local ethic committee a request for clinical use of identified compound.

Detailed description

This is a biological study for R/R T-ALL/LBL or ETP-ALL patients. Bone marrow and/or peripheral blood samples will be subjected to genomic, DSRP profiling and phosphoproteomic screening to identify novel potential therapeutic approach and thus, eligibility for treatment based on molecular and DSRP data. Genomic studies include karyotyping, CI-FISH and sequencing of 72 selected genes recurrently involved in T-ALL (by NGS). A panel of 80 compounds has been choosen for DSRP profile. As soon as genomic and DSRP profiling are made available, local Investigator can submit to local ethic committee a request for clinical use of compound hits. Meanwhile, in case of leukocytosis and uncontrolled disease, patients will be treated with cytoreductive therapies and best supportive care according to guidelines and scientific consensus. Every patient will receive a molecularly and functionally informed therapy following the therapeutic schedule already defined by in other tumors. Treatment will be selected on the basis of integration of genomic and small response data.

Conditions

Interventions

TypeNameDescription
OTHERbone marrow and/or peripheral blood samples withdrawalbone marrow and/or peripheral blood samples evaluation

Timeline

Start date
2021-05-19
Primary completion
2024-05-01
Completion
2024-05-01
First posted
2020-10-09
Last updated
2024-02-07

Locations

10 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT04582487. Inclusion in this directory is not an endorsement.